Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Tempest Therapeutics, Inc. TPST

Healthcare  —  Biotechnology
0.83 (0.02) (2.35%) as of 25 Sep
Market cap
$14.4M
P/E
0.0×
Revenue Champion (10y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Tempest Therapeutics, Inc. (TPST) Business Profile

Updated before January 2025

Company Overview

Tempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment. Founded in 2017 and headquartered in South San Francisco, California, TPST focuses on advancing small molecule and biologic therapies that target the tumor microenvironment and immune system to combat cancer. The company was established by a team of seasoned professionals with extensive experience in oncology and drug development. Key leadership includes CEO Tom Dubensky, Ph.D., who brings decades of expertise in immuno-oncology, and other executives with strong backgrounds in biotechnology and pharmaceutical industries.

Core Business Segments

Immuno-Oncology Therapeutics

Tempest Therapeutics specializes in immuno-oncology, focusing on therapies that modulate the tumor microenvironment to enhance the immune system’s ability to fight cancer. The company’s pipeline includes:

  • TPST-1120: A selective PPAR-alpha antagonist designed to inhibit tumor growth and improve immune response. TPST-1120 is being evaluated in clinical trials for various solid tumors.
  • TREX-1 Inhibitor Program: A novel approach targeting the TREX-1 enzyme to enhance immune activation and improve the efficacy of existing cancer therapies.

Combination Therapies

TPST is also exploring combination therapies that integrate its proprietary drugs with existing immunotherapies, such as checkpoint inhibitors, to enhance treatment outcomes. These combinations aim to address resistance mechanisms and improve patient response rates.

Research and Development Services

In addition to its therapeutic pipeline, TPST invests heavily in research and development (R&D) to discover and validate new targets within the tumor microenvironment. The company collaborates with academic institutions and industry partners to accelerate innovation.

Business Model

Tempest Therapeutics operates on a research-driven business model that integrates cutting-edge science with strategic partnerships. The company generates revenue primarily through licensing agreements, collaborations, and milestone payments from its partners. By focusing on early-stage drug development and leveraging partnerships for late-stage clinical trials and commercialization, TPST minimizes financial risk while maximizing its scientific impact. The company also invests in intellectual property to protect its innovations and maintain a competitive edge.

Strategic Direction

Tempest Therapeutics aims to become a leader in immuno-oncology by advancing its pipeline of first-in-class and best-in-class therapies. Key strategic priorities include:

  • Pipeline Expansion: TPST plans to broaden its therapeutic portfolio by identifying new targets and developing additional small molecule and biologic therapies.
  • Global Collaborations: The company seeks to establish partnerships with pharmaceutical companies and research institutions to accelerate clinical development and expand market reach.
  • Sustainability Goals: TPST is committed to sustainable practices in its operations, including reducing its environmental footprint and promoting diversity and inclusion within its workforce.
  • Regulatory Approvals: The company is focused on achieving regulatory milestones for its lead candidates, particularly TPST-1120, to bring its therapies to market.

Competitive Landscape

Tempest Therapeutics operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: A leader in immuno-oncology with a robust portfolio of checkpoint inhibitors.
  • Merck & Co.: Known for its blockbuster drug Keytruda, Merck is a major player in cancer immunotherapy.
  • Exelixis, Inc.: Focused on small molecule therapies for cancer treatment.
  • Arcus Biosciences: A clinical-stage biotech company developing innovative cancer therapies.

Despite the competition, TPST differentiates itself through its focus on the tumor microenvironment and its unique therapeutic approaches.

Risk Factors

Like any biotechnology company, Tempest Therapeutics faces several risks, including:

  • Clinical Trial Risks: The success of TPST’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approvals for new therapies is a complex and time-consuming process.
  • Market Dependence: TPST relies heavily on its lead candidates, such as TPST-1120, for future revenue growth.
  • Supply Chain Disruptions: The company’s operations could be impacted by disruptions in the supply chain for raw materials and manufacturing.
  • Competitive Pressure: Intense competition in the immuno-oncology space could limit TPST’s market share and profitability.

Recent Developments

Tempest Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trial Updates: Positive interim results from Phase 1/2 trials of TPST-1120 in combination with checkpoint inhibitors.
  • Partnership Announcements: New collaborations with leading pharmaceutical companies to co-develop and commercialize its therapies.
  • Corporate Milestones: Expansion of its leadership team and board of directors to include experts in oncology and drug development.
  • Global Developments: The COVID-19 pandemic has underscored the importance of resilient supply chains and adaptive clinical trial designs, which TPST has successfully implemented.

Investment Considerations

Strengths

  • Innovative Pipeline: TPST’s focus on first-in-class therapies targeting the tumor microenvironment sets it apart from competitors.
  • Experienced Leadership: The company’s management team has a proven track record in oncology and drug development.
  • Strategic Partnerships: Collaborations with industry leaders enhance TPST’s clinical and commercial capabilities.

Risks

  • High R&D Costs: Developing new therapies is capital-intensive and may not always yield successful outcomes.
  • Regulatory Uncertainty: Delays or failures in obtaining regulatory approvals could impact the company’s growth.
  • Market Competition: Intense competition in the immuno-oncology space poses a challenge to TPST’s market position.

Conclusion

Tempest Therapeutics, Inc. is well-positioned in the biotechnology sector with its innovative approach to cancer treatment. The company’s focus on the tumor microenvironment and its robust pipeline of therapies provide a strong foundation for future growth. While challenges such as regulatory hurdles and market competition remain, TPST’s strategic direction and experienced leadership offer a promising outlook for investors and stakeholders alike.